UK Announces Two Clinical Trials on Puberty Blockers for Young People with Gender Incongruence
Two new studies are underway in the UK to investigate the impact of puberty blockers, a treatment previously used mainly off-label for young people experiencing gender dysphoria. The trials, part of a larger "Pathways" program, aim to assess the effects of these medications on psychological and physical development among children and adolescents.
The first study, Pathways Trial, will recruit around 226 participants aged between 10-11 (females) and 11-12 (males), but actually older due to rigorous selection. Participants will be randomly assigned to start or delay using puberty blockers for a year, with all receiving comprehensive care and support during the trial period of up to 24 months.
The second study, Pathways Connect, will involve approximately 150 participants in the first trial as well as about 100 young people not receiving puberty blockers. These individuals will undergo MRI brain scans, followed by cognitive tasks and tests, providing a comparison group for analysis.
Experts have expressed concerns over the trials' design, with some labeling it "coercive in nature." Chay Brown, health director at TransActual, warned that this approach would subject young people to distressing pubertal changes while others benefit from delayed treatment. Emily Simonoff, lead investigator of the studies, acknowledged that such trials often precede wider availability of new medications.
The results of these studies will be crucial in shaping future healthcare policies for young people with gender incongruence. With no definitive evidence on long-term effects, researchers and clinicians must rely on observational data to inform their decisions. As the investigation unfolds, experts hope it will contribute meaningfully to understanding the role of puberty blockers in supporting young people's mental and physical health.
Two new studies are underway in the UK to investigate the impact of puberty blockers, a treatment previously used mainly off-label for young people experiencing gender dysphoria. The trials, part of a larger "Pathways" program, aim to assess the effects of these medications on psychological and physical development among children and adolescents.
The first study, Pathways Trial, will recruit around 226 participants aged between 10-11 (females) and 11-12 (males), but actually older due to rigorous selection. Participants will be randomly assigned to start or delay using puberty blockers for a year, with all receiving comprehensive care and support during the trial period of up to 24 months.
The second study, Pathways Connect, will involve approximately 150 participants in the first trial as well as about 100 young people not receiving puberty blockers. These individuals will undergo MRI brain scans, followed by cognitive tasks and tests, providing a comparison group for analysis.
Experts have expressed concerns over the trials' design, with some labeling it "coercive in nature." Chay Brown, health director at TransActual, warned that this approach would subject young people to distressing pubertal changes while others benefit from delayed treatment. Emily Simonoff, lead investigator of the studies, acknowledged that such trials often precede wider availability of new medications.
The results of these studies will be crucial in shaping future healthcare policies for young people with gender incongruence. With no definitive evidence on long-term effects, researchers and clinicians must rely on observational data to inform their decisions. As the investigation unfolds, experts hope it will contribute meaningfully to understanding the role of puberty blockers in supporting young people's mental and physical health.